ArticleEuropean journal of orthopaedic surgery & traumatology : orthopedie traumatologie2025
Cluster of differentiation 133 (CD133) and C-X-C chemokine receptor 4 (CXCR4) associated with the incidence of metastasis in osteosarcoma patients.
Article in European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma has a global incidence of 3.4 cases per million annually, with 10-20% of patients presenting with metastasis at diagnosis. Its high metastatic potential is attributed to a highly proliferative cell population and cancer stem cells that drive tumorigenesis and metastasis. This study examines the relationship between CD133 and CXCR4 expression and metastasis in osteosarcoma.
methodsUsing a cross-sectional approach, blood serum from osteosarcoma patients diagnosed at two centers was analyzed for CD133 and CXCR4 levels via Reed Biotech ELISA KIT. Absorbance quantified marker levels, and metastasis data were obtained from medical records. A chi-square test assessed the relationship between marker levels and metastasis, with significance set at p < 0.05.
resultsAmong 40 patients (80% < 40 years), mean CD133 was 0.23 ± 0.02 pg/ml and mean CXCR4 was 6015.82 ± 2345.55 pg/ml. CD133 and CXCR4 levels were significantly associated with metastasis (p = 0.009 and p < 0.001, respectively).
conclusionThese findings suggest that higher expression of CD133 and CXCR4 correlates with increased metastasis in osteosarcoma, underscoring their potential roles in predicting metastatic behavior and aiding in targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.